Pancreatic cancer Companies

Latest Pancreatic Cancer Companies Updates:

Pfizer's acquisition of Biohaven Pharmaceutical Holding Company: Gains access to innovative pancreatic cancer drug candidate.

Bristol Myers Squibb's collaboration with IFM Therapeutics: Jointly developing a novel targeted therapy for pancreatic cancer.

Merck & Co.'s partnership with Velontra Biosciences: Teams up to explore potential synergies in their respective pancreatic cancer pipelines.

Eli Lilly's Zydiso (nalurimide): Approved by the FDA for second-line treatment of pancreatic cancer, expanding treatment options.

Roche's Tecentriq (atezolizumab): Received breakthrough therapy designation from the FDA for combination use in early-stage pancreatic cancer.

AstraZeneca's Imfinzi (durvalumab): Market authorization extended in Europe for maintenance treatment of resectable pancreatic cancer.

List of Pancreatic Cancer Key companies in the market:

• Pharmacyte Biotech Inc. (U.S.)


• ncoGenex Pharmaceuticals Inc. (U.S.)


• Oncolytics Biotech (Canada)


• Diffusion Pharmaceuticals (U.S.)


• Polaris Pharmaceuticals, Inc. (U.S.)


• Sun BioPharma, Inc. (U.S.)


• Midatech Pharma PLC (U.K.)


• Eli Lilly and Company (U.S.)


• Celgene Corporation (U.S.)


• F. Hoffmann-La Roche AG (Switzerland)


• Amgen, Inc. (U.S.)


• Novartis International AG (U.S.)


• Clovis Oncology (U.S.